mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure
Journal of Molecular Psychiatry September 17, 2013 Jason M. Dwyer, Ashley E. Lepack, Ronald S. Duman 81 citations
BACKGROUND: Depression is a prevalent neuropsychiatric disorder that affects an estimated 350 million people worldwide. Currently available treatments for depression are lacking in both speed of onset and efficacy. Recent pharmacological efforts have targeted the glutamatergic neurotransmitter system using the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine to produce rapid and robust...